DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/592462/f_hoffmannla_roc) has announced the addition of the "F. Hoffmann-La Roche Ltd: PharmaVitae Profile" company profile to their offering.
This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs
Features and Benefits:
- Gain insight into Roche's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights:
Strategic insight into the prospects for Roche over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales
Your Key Questions Answered:
- Benchmark Roche's performance against key rivals in the prescription pharmaceutical sector
- Assess the importance of Genentech-sourced products to the future top-line performance of the Roche Group
- Discover the impact of Roche's desire to re-enter the primary care market, away from its current hospital care focus
Key Topics Covered:
Executive Summary
- Key findings
- Roche prescription pharmaceutical sales outlook
- Roche financial outlook
- Key developments
- SWOT analysis
About This Profile
- PharmaVitae Explorer database
- Chapter structure
- Strategic Insight
- Company Introduction
- Sales Analysis
- Financial Analysis
- Product Analysis
- Data sourcing
- Analyst consensus
Strategic Insight
- Key findings
- Strategic insight
- Genentech-sourced sales reliance
- A return to the primary care market?
Company Introduction
- Key findings
- Background
- Key corporate developments
- M&A history
Sales Analysis
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2004-
- Product analysis
- Product analysis
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Launch analysis
- Core analysis
- Expiry analysis
- Launch/core/expiry configuration, 2010-
- Molecule type analysis
- Externalization analysis
Financial Analysis
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004-
- Operating costs and profit analysis
- Operating costs and profit analysis, 2004-
- Operating cost ratio and profit margin analysis, 2004-
- Operating cost ratio and profit margin analysis, 2010-
- Operating costs and profit analysis, 2010-
Product Analysis
- Avastin
- MabThera
- Herceptin
- Tarceva
- Pegasys
- Lucentis
- Actemra
- CellCept
- Bonviva
- Tamiflu
For more information visit http://www.researchandmarkets.com/research/592462/f_hoffmannla_roc
Source: Datamonitor